Wockhardt Ltd (WOCKPHARMA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532300 | NSE: WOCKPHARMA | Pharmaceuticals & Drugs | Small Cap

Wockhardt Share Price

1,362.40 31.05 2.33%
as on 05-Dec'25 12:17

Wockhardt Ltd (WOCKPHARMA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532300 | NSE: WOCKPHARMA | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Wockhardt

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Wockhardt stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
0.00
Market Cap:
21,633.4 Cr.
52-wk low:
1,109.6
52-wk high:
1,870

Is Wockhardt Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Wockhardt: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Wockhardt Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 6.9%-0.3%-5.5%-2.9%-1.1%-5.5%-2%-5.9%-2.2%4.1%-
Value Creation
Index
-0.5-1.0-1.4-1.2-1.1-1.4-1.1-1.4-1.2-0.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 4,4534,0153,9373,5662,8442,7083,2302,6512,7983,0122,984
Sales YoY Gr.--9.9%-1.9%-9.4%-20.2%-4.8%19.3%-17.9%5.6%7.7%-
Adj EPS 21.8-17.9-37.1-22.6-14.9-22-8.6-29.8-27.3-2.7-1.4
YoY Gr.--182.1%NANANANANANANANA-
BVPS (₹) 312.4275.1234.5220219.8280.5266231.8217.3268281.1
Adj Net
Profit
261-215-445-272-179-265-124-429-418-44.2-23
Cash Flow from Ops. 71.6-26968.4183649-287413153219-22-
Debt/CF from Ops. 37.4-15.454.818.45-8.14.512.39.6-84.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -4.3%1.2%-2.3%7.7%
Adj EPS -179.4%NANANA
BVPS-1.7%4%0.2%23.3%
Share Price -1.3% 27.3% 79.5% -5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
7-6-14.4-9.8-6.7-8.8-3.4-11.9-12.5-1.2-0.5
Op. Profit
Mgn %
11.40.7-1.4-0.43.4-2.39.23.93.313.214.1
Net Profit
Mgn %
5.9-6.1-12.8-8.3-5.4-9.7-4.9-18.5-15.3-1.8-0.8
Debt to
Equity
0.71.31.31.31.20.70.50.60.60.40.4
Working Cap
Days
223242233255320180161188198185152
Cash Conv.
Cycle
991341161141303710-7152541

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Wockhardt Ltd.

Standalone Consolidated
TTM EPS (₹) 8.7 -1.4
TTM Sales (₹ Cr.) 1,473 2,984
BVPS (₹.) 177.6 281.1
Reserves (₹ Cr.) 2,805 4,486
P/BV 7.50 4.74
PE 153.43 0.00
From the Market
52 Week Low / High (₹) 1109.60 / 1870.00
All Time Low / High (₹) 62.20 / 1996.06
Market Cap (₹ Cr.) 21,633
Equity (₹ Cr.) 81.3
Face Value (₹) 5
Industry PE 40.7

Management X-Ray of Wockhardt:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *69.0864.3874.5152.9037.4733.6416.9818.2415.6421.30
* Pledged shares as % of Promoter's holding (%)

Valuation of Wockhardt - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Wockhardt

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales4,4534,0153,9373,5662,8442,7083,2302,6512,7983,012
Operating Expenses 3,9594,0023,9923,6042,7462,7712,9322,5502,7592,619
Manufacturing Costs366290213247206227267229249283
Material Costs1,6141,6621,7981,6361,2031,1351,2671,1111,1651,132
Employee Cost 951967937800743763749637629651
Other Costs 1,0281,0841,045921593646649573716553
Operating Profit 49413-55-3898-6329810139393
Operating Profit Margin (%) 11.1%0.3%-1.4%-1.1%3.4%-2.3%9.2%3.8%1.4%13.0%
Other Income 661141772160132201228362
Interest 129225255265276249299302305254
Depreciation 142149150164224246247251223217
Exceptional Items 00-35800-142-183-294-140
Profit Before Tax 289-247-641-447-342-568-411-624-420-16
Tax 38-2126-135-204-271-132-35241
Profit After Tax 252-226-667-312-138-297-279-621-472-57
PAT Margin (%) 5.6%-5.6%-16.9%-8.7%-4.9%-11.0%-8.6%-23.4%-16.9%-1.9%
Adjusted EPS (₹)20.9-16.3-50.7-16.2-5.857.5-16.9-38.8-30.1-2.9
Dividend Payout Ratio (%)0%-56%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 3,7463,3002,8152,6432,6423,3483,8313,3383,3464,341
Share Capital 55555555555572727781
Reserves 3,6913,2442,7602,5872,5863,2933,7593,2663,2694,260
Minority Interest465382346330386383353308303304
Debt2,4713,8532,6102,4532,1451,5691,3891,5541,7231,707
Long Term Debt1,9213,1902,1731,8911,2415033552248911,211
Short Term Debt5506634375629041,0661,0341,330832496
Trade Payables638534602840895696921867766592
Others Liabilities 6567801,6051,3051,6821,3801,1761,008932642
Total Liabilities 7,9768,8497,9787,5717,7497,3767,6707,0757,0707,586

Fixed Assets

Gross Block4,3775,4565,7726,1136,7035,6566,0195,6965,7215,814
Accumulated Depreciation1,5682,6842,8843,0553,2012,3132,5572,6542,8403,078
Net Fixed Assets 2,8092,7732,8883,0583,5023,3433,4623,0422,8812,736
CWIP 1,0361,2441,4331,4451,5851,3791,3421,5391,7222,033
Investments 0563214000000422
Inventories1,1021,108856819716799769658640725
Trade Receivables1,1111,0349621,2741,243918918797618661
Cash Equivalents 1,4781,6041,082449268292406124529191
Others Assets 439524544525435645773915680818
Total Assets 7,9768,8497,9787,5717,7497,3767,6707,0757,0707,586

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 72-26968183649-287413153219-22
PBT 289-247-641-300-197916-411-624-420-16
Adjustment 262303449445483-943554635677455
Changes in Working Capital -396-29727880380-143367153-8-492
Tax Paid -84-28-18-41-17-117-97-11-3031
Cash Flow From Investing Activity -818-68763095-1561,470-201-125-137-783
Capex -492-409-306-270-163-69-211-130-150-355
Net Investments 373-52044021300000-404
Others -69924249615181,53910513-24
Cash Flow From Financing Activity 2541,254-769-776-680-1,171-71-315334409
Net Proceeds from Shares 86000007480468983
Net Proceeds from Borrowing 671,478-306-619-601-783-737-290-293-338
Interest Paid -88-206-233-259-248-235-190-242-197-148
Dividend Paid 0-138-0-00-1-2000
Others 190121-231101169-152110217356-88
Net Cash Flow -492298-71-499-18612141-287416-396

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)7.07-6.42-21.81-11.43-5.22-9.92-7.77-17.32-14.12-1.48
ROCE (%)6.87-0.31-5.47-2.87-1.11-5.5-1.96-5.88-2.154.07
Asset Turnover Ratio0.580.480.470.460.370.610.680.580.510.53
PAT to CFO Conversion(x)0.29N/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days7698931141618565737260
Inventory Days871009186996056616664
Payable Days135129115161263256233294256219

Wockhardt Ltd Stock News

Wockhardt Ltd FAQs

The current trading price of Wockhardt on 05-Dec-2025 12:17 is ₹1,362.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Wockhardt stood at ₹21,633.4.
The latest P/E ratio of Wockhardt as of 04-Dec-2025 is 153.4.
The latest P/B ratio of Wockhardt as of 04-Dec-2025 is 7.50.
The 52-week high of Wockhardt is ₹1,870 and the 52-week low is ₹1,109.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Wockhardt is ₹1,473 ( Cr.) .

About Wockhardt Ltd

Wockhardt Ltd. is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. It is a true Indian Multi-National Company with a multi-ethnic workforce of many Wockhardt Associates from many different nationalities globally. It has many research centres and several manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. It is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt.

Business area of the company

The company is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.

Awards

2009

  • Outstanding National Citizen Award by National Citizens Guild.
  • Strathmore’s Who’s Who - Social Entrepreneur of the Year.

2010

  • AmeriCares India Spirit of Humanity Award.
  • USA BF Foundation of the Year Award.
  • HEF Award for ‘Outstanding contribution to the teaching community with special reference to Human Values.
  • Best Pharma CSR award at the Pharmaceutical Leadership Summit.

2011

  • IDF - CSR Award.

2012

  • Inclusive India Award under the Corporate category for ‘Best Social Work in the Realm of Primary Healthcare’.
  • IPE CSR Corporate Governance Award.

2013

  • Rajiv Gandhi Global Excellence Award.
  • Rajiv Gandhi Excellence Award.
  • Bharat Gaurav Award.
  • Asian CSR Leadership Awards.
  • CSR Excellence & Leadership Award.
  • Asia Peace Award.

2015

  • Best CSR Project in Healthcare for Mobile 1000 Medical vans - India CSR.
  • Best Community Development Award for Mobile 1000 - World CSR Congress.
  • CSR Professional of the Year - World CSR Congress.
  • Maharashtra Class Owners Association Meritorious Award for valuable contribution in the field of education.
  • Bronze Award for Table Calendar - A.B.C.I (Association of Business Communicators of India).
  • Social Entrepreneur of the Year 2015 - Pharma Leaders.
  • Swachh Bharat Samman - India CSR.
  • Best Environment Friendly Project for Bio-Toilets - Asian CSR Leadership Awards.

2016

  • CSR Leadership Award.
  • Lions CSR Precious Award.
  • Champion of WSIS Prize 2016 - World Summit on the Information Society.
  • Outstanding Leadership Award - Nurturing the Future Foundation.
  • Peace Leader of the Year 2016 - 7th India Leadership Conclave and Indian Affairs Business Leadership Awards 2016.
  • Best Service Award for Significant National Contribution - Institute of Technology & Science.
  • Asia Healthcare Excellence Award - CMO Asia.

2017

  • Excellence Award for Corporate Social Responsibility & Peace Mission - Indian Virtual University for Peace and Education (IVUP).
  • Global NGO Excellence Award for Excellence in Mother & Child Care - World CSR Day.
  • CSR Humanity Award’ by India CSR.
  • Lifetime Achievement Award from the National Institute of Cleanliness Education and Research (NICER).
  • Indian of the Year 2017 (Social Service) by ILC Power Brand.
  • The Rotary Peace Ambassador Award by Rotary.
  • CSR Impact Award by IndiaCSR.
  • Magnificient Man Choice Award with specialization in CEO CSR Excellence from Hopewill International Business Academy.

2018

  • Game Changer Award by The HR Club.
  • Sabarmati Festival Foundation Award for Outstanding Social Work from Sabarmati Festival Foundation.
  • Divyang Ratna Award 2018 by Disable Welfare Trust of India.

2019

  • Mumbai Heroes Award from Blossom Media Pvt Ltd at the Humanity First Conclave.
  • Inspiring Indian Award from Indian Ex Defence Service Employees Chamber of Commerce & Industries (IESECCI).
  • Award for Peace Mobilization from Poddar Foundation at the Insure your Mental Health Conference (Celebrating World Health Day).
  • Inspirational Indian of the Year at the The Mumbai Achievers Awards 2019 by Mumbai Halchal.
  • Bharat Shree Award 2019.
  • Rotary Award from Rotary Club of Mumbai Khar.
  • H F F Excellence Award from Humanity First Foundation.

2020

  • ‘For the Sake of Honour’ Award from Rotary.
  • Excellence in Human Welfare Award from Charity with a Twist, Nargis Dutt Foundation, ECOMO.

Milestones

2010

  • Wockhardt receives US FDA approval for antibacterial Levofloxacin.
  • Wockhardt launches Prostate drug Flomax in the United States on Day-1.
  • Wockhardt receives US FDA approval for the generic version of Toprol XL, a cardiac drug.

2011

  • Wockhardt launches generic version of Protonix tablets in the US.
  • Wockhardt receives US FDA approval for generic version of Effexor XR capsules.
  • Wockhardt launches three new products in three weeks, in the United States.
  • Wockhardt receives tentative US FDA approval for generic version of Patanol ophthalmic solution.

2012

  • Wockhardt launches generic version of anti-­ulcer drug Prevacid.
  • Wockhardt receives US FDA approval for generic version of Parkinsonism drug Requip XL.
  • Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodon.
  • Wockhardt receives US FDA approval for generic version of Parkinson’s drug Comtan.

2013

  • Wockhardt receives the 'Best Enterprise' award from the Europe Business Assembly.
  • Wockhardt launches generic version of anti-convulsant drug Lamictal XR.

2014

  • Wockhardt’s drug discovery gets a boost with fast track approval by USFDA.

2015

  • Wockhardt Receives ANDA Approval for pain medication Oxycodone liquid.
  • Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -US FDA grants breakthrough (QIDP) drug discovery status to the New Antibiotic of Wockhardt.

2018

  • Wockhardt sets up its first manufacturing and R&D unit in Middle East.

2019

  • Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 50mg injection of Decitabine, which is used to treat certain forms of cancer.
  • Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 100mg and 400mg tablets of Imatinib Mesylate, which is used to treat many kinds of cancers and tumors.

2020

  • Wockhardt has entered into an agreement with the UK Government to fill finish COVID-19 vaccines.
  • Wockhardt has received approval from Indian drug regulator -- Drug Controller General of India (DCGI) for 2 new antibiotics, EMROK (IV) and EMROK O (Oral), which is used to treat acute bacterial skin and skin structure Infections including diabetic foot infections and concurrent bacteraemia based on the Phase 3 study involving 500 patients in 40 centres across India.
  • Wockhardt has received approval for the transfer of business comprising 62 products and line extensions along with related business assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives; and manufacturing facility in Baddi, Himachal Pradesh, India, where some of the said pharmaceutical products which are being transferred are manufactured and together referred to as the Business Undertaking by way of a slump sale to Dr. Reddy's Laboratories for Rs 1,850 crore as per the terms and conditions specified in the Business Transfer Agreement (BTA).
  • Wockhardt announced COVID-19 vaccine partnership with UK Government.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×